Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Steinberg and colleagues1 reported a 40% reduction in mortality among patients
with SCA who used hydroxyurea (P = .04), without
statistically significant toxicity. The authors pointed out that theirs was
an observational study of self-selected treatment. Despite the authors' caution,
we are concerned that they are overly optimistic in their conclusions.
Lee DA, Mueller BU. Long-term Use of Hydroxyurea for Sickle Cell AnemiaLong-term Use of Hydroxyurea for Sickle Cell Anemia. JAMA. 2003;290(6):752. doi:10.1001/jama.290.6.752-a
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: